PCIA
ALDX icon

Prime Capital Investment Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Prime Capital Investment Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$49.9K – 1071
2024
Q4 		$49.9K Hold
10,000
– – ﹤0.01% 917
2024
Q3 		$53.9K Hold
10,000
– – ﹤0.01% 901
2024
Q2 		$33.1K Sell
10,000
-5
-0% -$20 ﹤0.01% 908
2024
Q1 		$32.7K Sell
10,005
-83
-0.8% -$273 ﹤0.01% 988
2023
Q4 		$35.4K Buy
+10,088
New +$31.1K ﹤0.01% 943

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Prime Capital Investment Advisors's ALDX Position: Q1 2025 in Review

Prime Capital Investment Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2025, closing a stake of 10,000 shares — an estimated $49.9K sold.

Prime Capital Investment Advisors first reported a position in ALDX in Q4 2023 and held it in 5 quarters. The position peaked at $53.9K in Q3 2024. 125 funds tracked by Wall St. Rank hold ALDX as of Q1 2025.

  • Prime Capital Investment Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 10,000 Aldeyra Therapeutics shares in Q1 2025, an estimated $49.9K.
  • Prime Capital Investment Advisors first reported a position in Aldeyra Therapeutics in Q4 2023 and held it in 5 quarters.
  • Prime Capital Investment Advisors's Aldeyra Therapeutics position peaked at $53.9K in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2025.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2025, filed 13 May 2025.